1-(1-bromoethyl)-4-(trifluoromethoxy)benzene | 68120-57-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-(1-bromoethyl)-4-(trifluoromethoxy)benzene
• CAS: 68120-57-0
• 化学式: C₉H₈BrF₃O
• mdl: MFCD11180332
• 分子量: 269.061
• InChiKey: RNXABUQTPSAAJW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N,N'-二甲基-1H-咪唑-4,5-二甲酰胺 、 1-(1-bromoethyl)-4-(trifluoromethoxy)benzene 生成 1-[1-(4-trifluoromethoxy-phenyl)-ethyl]-1H-imidazole-4,5-dicarboxylic acid bis-methylamide
  参考文献：
  名称：

  GILMOUR, J.;HATTON, L. R.;PARNELL, E. W.;WARBURTON, D.;LEEDS, W. G.

  摘要：

  DOI：
• 作为产物：
  描述：

  1-[4-(三氟甲氧基)苯基]乙醇 在 三溴化磷 作用下， 反应 2.0h， 以100%的产率得到1-(1-bromoethyl)-4-(trifluoromethoxy)benzene
  参考文献：
  名称：

  Synthesis and Structure–Activity Relationships of Varied Ether Linker Analogues of the Antitubercular Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)

  摘要：

  New analogues of antitubercular drug PA-824 were synthesized, featuring alternative side chain ether linkers of varying size and flexibility, seeking drug candidates with enhanced metabolic stability and high efficacy. Both alpha-methyl substitution and removal of the benzylic methylene were broadly tolerated in vitro, with a biaryl example of the latter class exhibiting an 8-fold better efficacy than the parent drug in a mouse model of acute Mycobacterium tuberculosis infection and negligible fragmentation to an alcohol metabolite in liver microsomes. Extended linkers (notably propenyloxy, propynyloxy, and pentynyloxy) provided greater potencies against replicating M. tb (monoaryl analogues), with propynyl ethers being most effective under anaerobic (nonreplicating) conditions (mono/biaryl analogues). For benzyloxybenzyl and biaryl derivatives, aerobic activity was maximal with the original (OCH2) linker. One propynyloxy-linked compound displayed an 89-fold higher efficacy than the parent drug in the acute model, and it was slightly superior to antitubercular drug OPC-67683 in a chronic infection model.

  DOI：

  10.1021/jm200377r

文献信息

• [EN] FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES CONDENSÉS À TITRE DE MODULATEURS DE S1P
  申请人：ABBVIE INC

  公开号：WO2017036978A1

  公开（公告）日：2017-03-09

  The invention relates to heterocyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.

  这项发明涉及杂环化合物作为S1P调节剂，包括这种化合物的药物组合物，以及在治疗、缓解或预防由S1P受体介导的疾病或紊乱中的用途。
• [EN] LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE LACTAME UTILES EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2012063207A1

  公开（公告）日：2012-05-18

  The present invention relates to lactam derivatives of formula (I) wherein Y, R1, R2 and R3 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.

  本发明涉及公式（I）的内酰胺衍生物，其中Y、R1、R2和R3如描述中所述，以及它们的制备方法，其药学上可接受的盐，以及它们作为药物的用途，包括含有一个或多个公式（I）化合物的药物组合物，特别是它们作为促进睡眠的药物受体拮抗剂的用途。
• Substituted azole derivatives, compositions, and methods of use
  申请人：Mjalli M.M. Adnan

  公开号：US20050187277A1

  公开（公告）日：2005-08-25

  The present invention provides azole derivatives of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I), and their use in treating human or animal disorders. The compounds of the invention can be useful as inhibitors of protein tyrosine phosphatases and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes.

  本发明提供了式（I）的唑类衍生物，其制备方法，包含式（I）化合物的药物组合物，以及它们在治疗人类或动物疾病中的用途。本发明的化合物可用作蛋白酪氨酸磷酸酶的抑制剂，因此可用于管理、治疗、控制或辅助治疗由PTPase活性介导的疾病。这些疾病包括I型糖尿病和II型糖尿病。
• Substituted Azole Derivatives, Compositions, and Methods of Use
  申请人：Mjalli Adnan M.M.

  公开号：US20110092553A1

  公开（公告）日：2011-04-21

  The present invention provides azole derivatives of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I), and their use in treating human or animal disorders. The compounds of the invention can be useful as inhibitors of protein tyrosine phosphatases and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes.

  本发明提供式（I）的唑类衍生物，其制备方法，含有式（I）化合物的制药组合物，以及它们在治疗人类或动物疾病方面的用途。本发明的化合物可用作蛋白酪氨酸磷酸酶的抑制剂，因此可用于治疗PTPase活性介导的疾病的管理、治疗、控制或辅助治疗。这些疾病包括1型糖尿病和2型糖尿病。
• LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS
  申请人：Aissaoui Hamed

  公开号：US20130237525A1

  公开（公告）日：2013-09-12

  The present invention relates to lactam derivatives of formula (I) wherein Y, R 1 , R 2 and R 3 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.

  本发明涉及式(I)的内酰胺衍生物，其中Y、R1、R2和R3如描述中所述，以及它们的制备方法、药学上可接受的盐和它们作为药物的用途，含有一个或多个式(I)化合物的药物组合物，特别是它们作为促进睡眠的药物。